Evidence map›Paper›PMID 36538034›Full record

ArticleExpert opinion on drug safety2022

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

I R Reid

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Expert opinion on drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Cardiovascular safety of osteoanabolic agents.Journal of bone and mineral metabolism · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

I R ReidDepartment of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.ORCID 0000-0001-6021-5458
University of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone Density Conservation AgentsCardiovascular DiseasesOsteoporosisOsteoporosis, PostmenopausalAntibodies, MonoclonalBone DensityFemaleHumansAntibodies, MonoclonalBone Density Conservation Agentsromosozumabcardiovascular diseaseosteoporosisromosozumab

Identifiers

PMID36538034
OpenAlexW4312211099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.